UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 10, 2018
BIO-PATH HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36333 | 87-0652870 |
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
4710 Bellaire Boulevard, Suite 210, Bellaire, Texas | 77401 |
(Address of principal executive offices) | (Zip Code) |
(832) 742-1357
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On May 10, 2018, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board.” A copy of such press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit | |
Number | Description |
99.1 | Press Release titled “Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-PATH HOLDINGS, Inc. | |||
Dated: May 10, 2018 | By: | /s/ Peter H. Nielsen | |
Peter H. Nielsen | |||
President and Chief Executive Officer |
EXHIBIT INDEX
Exhibit | |
Number | Description |
99.1 | Press Release titled “Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board” |
Exhibit 99.1
Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board
HOUSTON—May 7, 2018 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Anas Younes, M.D., to its Scientific Advisory Board (SAB).
“It is with great pleasure we welcome Dr. Younes, one of the world’s most renowned lymphoma experts, to our SAB. His considerable expertise in hematological cancers will be of significant value to Bio-Path as we advance our oncology programs. In particular, his guidance will be key as we develop our program for BP1002 in lymphoma and solid tumors,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path.
“Bio-Path is developing a truly innovative platform that has the potential to significantly enhance therapies for cancers of unmet need,” commented Dr. Younes. “I’m delighted to offer my insights and work with this SAB to help advance DNAbilize™ to offer meaningful new treatments to patients.”
Dr. Younes is a Professor and Chief of Lymphoma Service at Memorial Sloan Kettering Cancer Center (MSK). Prior to joining MSK, he spent more than 20 years at M.D. Anderson Cancer Center, most recently as Director of Clinical and Translational Medicine in the Department of Lymphoma and Myeloma.
Dr. Younes received his M.D. from the University of Damascus School of Medicine. He completed his internal medicine residency training at SUNY Downstate Medical Center and his pathology residency at the Medical College of Ohio. He completed his hematology fellowship training at MSK.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
# # #
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
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end